How much funding has Annexon, Inc. raised?

Annexon, Inc. has raised $500.0M in total funding, most recently a Series E round.

Who are Annexon, Inc.'s investors?

Annexon, Inc.'s investors include GV, Alta Partners, Bain Capital Life Sciences, Goldman Sachs, Wells Fargo, Omega Funds.

When was Annexon, Inc. founded?

Annexon, Inc. was founded in 2016.

Where is Annexon, Inc. headquartered?

Annexon, Inc. is headquartered in South San Francisco, California, United States.

What industry is Annexon, Inc. in?

Annexon, Inc. operates in Biopharmaceutical, Biotech, Healthcare.

How many employees does Annexon, Inc. have?

Annexon, Inc. has 1-10 employees.

Annexon, Inc.

Unlocking the next generation of complement therapies

South San Francisco, United States · Founded 2016 · $500.0M raised

Biopharmaceutical

Biotech

Healthcare

Headquarters: South San Francisco, California
Employees: 1–10
Founded: 2016
Business Model: B2B

Website: annexonbio.com
Total Funding: $500.0M
Last Round: Series ENov 2025
Rounds: 6

About

Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines targeting the classical complement pathway via C1q inhibition. Its pipeline addresses autoimmune, neurodegenerative, and ophthalmic disorders, with candidates including ANX005, ANX007, and ANX009 in clinical development. The company was founded in 2011 by Arnon Rosenthal and Ben Barres.

Summary

Annexon, Inc. is a Biopharmaceutical company based in South San Francisco, United States, founded in 2016. It has raised $500.0M in total across 6 rounds, most recently a Series E round in Nov 2025. Investors include GV, Alta Partners and Bain Capital Life Sciences.

LinkedIn X (Twitter)